1-20 of 65
Robert M. Sharkey
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3193: Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51

Thomas M. Cardillo, Ali A. Mostafa, Diane L. Rossi, Donglin Liu, Chien-Hsing Chang, Robert M. Sharkey, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3193.
https://doi.org/10.1158/1538-7445.AM2017-3193
Published: 01 July 2017
View articletitled, Abstract 3193: Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
Journal Articles

Abstract CT155: Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)

Jhanelle E. Gray, Rebecca S. Heist, Alexander N. Starodub, D. Ross Camidge, Ebenezer Kio, Gregory Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Charles J. Schneider, Bryan J. Schneider, Allyson J. Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): CT155.
https://doi.org/10.1158/1538-7445.AM2017-CT155
Published: 01 July 2017
View articletitled, Abstract CT155: Phase 2 study of sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), in patients with pretreated metastatic small-cell lung cancer (mSCLC)
Journal Articles

Abstract 4081: Superior SN-38 pharmacodynamic and tumor-accretion profiles of labetuzumab govitecan (IMMU-130) versus irinotecan in experimental human colonic cancer models

Thomas M. Cardillo, Robert M. Sharkey, Serengulam V. Govindan, Jennifer Donnel, Maria Zalath, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 4081.
https://doi.org/10.1158/1538-7445.AM2017-4081
Published: 01 July 2017
View articletitled, Abstract 4081: Superior SN-38 pharmacodynamic and tumor-accretion profiles of labetuzumab govitecan (IMMU-130) versus irinotecan in experimental human colonic cancer models
Journal Articles

Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors

Robert M. Sharkey, Allyson J. Ocean, Alexander N. Starodub, Aditya Bardia, Michael Guarino, Wells A. Messersmith, Jordan D. Berlin, Vincent J. Picozzi, Rebecca Moroose, William A. Wegener, Pius Maliakal, Serengulam V. Govindan, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 3734.
https://doi.org/10.1158/1538-7445.AM2017-3734
Published: 01 July 2017
View articletitled, Abstract 3734: Pharmacokinetics of sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) targeting Trop-2, in patients with diverse advanced solid tumors
Journal Articles

Abstract 584: Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors

Thomas M. Cardillo, Serengulam V. Govindan, Maria Zalath, Ali Mostafa, Roberto Arrojo, Robert M. Sharkey, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 584.
https://doi.org/10.1158/1538-7445.AM2016-584
Published: 15 July 2016
View articletitled, Abstract 584: Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors
Journal Articles

Abstract 587: Superior anti-tumor effects of an anti-HLA-DR IgG4 antibody, IMMU-114, in chronic and acute lymphocytic leukemia (CLL and ALL): Comparison to anti-CD20 therapy, chemotherapy, or combined with kinase inhibitors

Thomas M. Cardillo, Maria Zalath, Roberto Arrojo, Robert M. Sharkey, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 587.
https://doi.org/10.1158/1538-7445.AM2016-587
Published: 15 July 2016
View articletitled, Abstract 587: Superior anti-tumor effects of an anti-HLA-DR IgG4 antibody, IMMU-114, in chronic and acute lymphocytic leukemia (CLL and ALL): Comparison to anti-CD20 therapy, chemotherapy, or combined with kinase inhibitors
Journal Articles

Abstract CT065: Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results

Efrat Dotan, Steven J. Cohen, Alexander N. Starodub, Christopher H. Lieu, Wells A. Messersmith, Michael J. Guarino, John L. Marshall, Richard M. Goldberg, J. Randolph Hecht, Pius Maliakal, William A. Wegener, Robert M. Sharkey, Francois Wilhelm, Lucy Lee, David M. Goldenberg, Jordan D. Berlin
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT065.
https://doi.org/10.1158/1538-7445.AM2016-CT065
Published: 15 July 2016
View articletitled, Abstract CT065: Labetuzumab govitecan (IMMU-130), an anti-CEACAM5/SN-38 antibody-drug conjugate, is active in patients (pts) with heavily pretreated metastatic colorectal cancer (mCRC): phase II results
Journal Articles

Abstract CT064: Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience

Scott T. Tagawa, Bishoy Faltas, Elaine Lam, Wells A. Messersmith, Philip Saylor, Aditya Bardia, Julio J. Hajdenberg, Alicia K. Morgans, Jordan D. Berlin, Emerson Lim, Kevin Kalinsky, Pius Maliakal, Robert M. Sharkey, Francois Wilhelm, David M. Goldenberg, Allyson J. Ocean
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT064.
https://doi.org/10.1158/1538-7445.AM2016-CT064
Published: 15 July 2016
View articletitled, Abstract CT064: Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience
Journal Articles

Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results

Alexander N. Starodub, Allyson J. Ocean, Aditya Bardia, Michael J. Guarino, Wells Messersmith, Jordan Berlin, Vincent J. Picozzi, Sajeve S. Thomas, Gregory Masters, Linda T. Vahdat, Ingrid A. Mayer, Rebecca Moroose, Jennifer S. Diamond, Scott T. Tagawa, Manish A. Shah, Francois Wilhelm, William A. Wegener, Pius Maliakal, Robert M. Sharkey, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2015) 75 (15_Supplement): CT236.
https://doi.org/10.1158/1538-7445.AM2015-CT236
Published: 01 August 2015
View articletitled, Abstract CT236: Advanced solid cancer therapy with a novel antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): key preclinical and clinical results
Journal Articles

Abstract P5-01-01: Pretargeted immuno-PET with an anti-carcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and a 68Ga-labeled hapten-peptide compared to conventional imaging and FDG-PET in metastatic breast cancer patients (BC): First results

Mario Campone, Aurore Rauscher, Alain Faivre-Chauvet, Thomas Carlier, Ludovic Ferrer, Pierre Baumgartner, David M Goldenberg, Robert M Sharkey, Jacques Barbet, Françoise Kraeber-Bodéré, Caroline Rousseau
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-01-01.
https://doi.org/10.1158/1538-7445.SABCS14-P5-01-01
Published: 01 May 2015
View articletitled, Abstract P5-01-01: Pretargeted immuno-PET with an anti-carcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and a 68Ga-labeled hapten-peptide compared to conventional imaging and FDG-PET in metastatic breast cancer patients (BC): First results
Journal Articles

Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results

David M Goldenberg, Linda T Vahdat, Alexander N Starodub, Aditya Bardia, Ellen Chuang, Rebecca L Moroose, Jennifer R Diamond, Robert M Sharkey, Pius P Maliakal, Steven A Hamburger, Allyson J Ocean
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-19-08.
https://doi.org/10.1158/1538-7445.SABCS14-P5-19-08
Published: 01 May 2015
View articletitled, Abstract P5-19-08: IMMU-132, a potential new antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC): Preclinical and initial clinical results
Journal Articles

Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)

Aditya Bardia, Alexander Starodub, Rebecca L Moroose, Ingrid A Mayer, Jennifer R Diamond, Ellen Chuang, Serengulam V Govindan, Robert M Sharkey, Pius Maliakal, William A Wegener, Steven A Hamburger, Allyson J Ocean, David M Goldenberg, Linda T Vahdat
Journal: Cancer Research
Cancer Res (2015) 75 (9_Supplement): P5-19-27.
https://doi.org/10.1158/1538-7445.SABCS14-P5-19-27
Published: 01 May 2015
View articletitled, Abstract P5-19-27: IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
Journal Articles

Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer

Susanne Lütje, Mark Rijpkema, David M. Goldenberg, Catharina M. van Rij, Robert M. Sharkey, William J. McBride, Gerben M. Franssen, Cathelijne Frielink, Wijnand Helfrich, Wim J.G. Oyen, Otto C. Boerman
Journal: Cancer Research
Cancer Res (2014) 74 (21): 6216–6223.
https://doi.org/10.1158/0008-5472.CAN-14-0594
Published: 30 October 2014
View articletitled, Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer
Open the PDF for Pretargeted Dual-Modality Immuno-SPECT and Near-Infrared Fluorescence Imaging for Image-Guided Surgery of Prostate Cancer in another window
Journal Articles

Abstract 2904: SN-38 antibody-drug conjugates as a novel platform for solid cancer therapy: preclinical science

David M. Goldenberg, Thomas M. Cardillo, Robert M. Sharkey, William J. McBride, Edmund A. Rossi, Chien-Hsing Chang, Serengulam V. Govindan
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2904.
https://doi.org/10.1158/1538-7445.AM2014-2904
Published: 01 October 2014
View articletitled, Abstract 2904: SN-38 antibody-drug conjugates as a novel platform for solid cancer therapy: preclinical science
Journal Articles

Abstract CT206: SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results

Alexander N. Starodub, Allyson J. Ocean, Manish A. Shah, Linda T. Vahdat, Ellen Chuang, Michael J. Guarino, Vincent J. Picozzi, Sajeve S. Thomas, Pius P. Maliakal, Serengulam V. Govindan, William A. Wegener, Robert M. Sharkey, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT206.
https://doi.org/10.1158/1538-7445.AM2014-CT206
Published: 01 October 2014
View articletitled, Abstract CT206: SN-38 antibody-drug conjugate (ADC) targeting Trop-2, IMMU-132, as a novel platform for the therapy of diverse metastatic solid cancers: Initial clinical results
Journal Articles

Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies

Neil H. Segal, Efrat Dotan, Jordan D. Berlin, Alexander N. Starodub, Michael J. Guarino, Leonard B. Saltz, Pius P. Maliakal, Serengulam V. Govindan, William A. Wegener, Robert M. Sharkey, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): CT211.
https://doi.org/10.1158/1538-7445.AM2014-CT211
Published: 01 October 2014
View articletitled, Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC) targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): Initial clinical results of two Phase I studies
Journal Articles

Abstract LB-159: A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC).

Neil H. Segal, Jaclyn Verghis, Serengulam Govindan, Pius Maliakal, Robert M. Sharkey, William A. Wegener, David M. Goldenberg, Leonard B. Saltz
Journal: Cancer Research
Cancer Res (2013) 73 (8_Supplement): LB-159.
https://doi.org/10.1158/1538-7445.AM2013-LB-159
Published: 15 April 2013
View articletitled, Abstract LB-159: A Phase I study of IMMU-130 (labetuzumab-SN38) anti-CEACAM5 antibody-drug conjugate (ADC) in patients with metastatic colorectal cancer (mCRC).
Journal Articles

Abstract 1755: Pretargeted radioimmunotherapy of an anti-CEA bispecific antibody and 177Lu-labeled peptide: a phase I study in patients with advanced colorectal cancer

Rafke Schoffelen, Otto C. Boerman, David M. Goldenberg, Robert M. Sharkey, Carla M.L. Herpen, Chien-Hsing Chang, Gerben M. Franssen, William J. McBride, Edmund A. Rossi, Winette T. A. van der Graaf, Wim J.G. Oyen
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 1755.
https://doi.org/10.1158/1538-7445.AM2012-1755
Published: 15 April 2012
View articletitled, Abstract 1755: Pretargeted radioimmunotherapy of an anti-CEA bispecific antibody and 177Lu-labeled peptide: a phase I study in patients with advanced colorectal cancer
Journal Articles

Abstract 2526: Optimal cleavable linker for antibody-SN-38 conjugates for cancer therapy: Impact of linker's stability on efficacy

Serengulam V. Govindan, Thomas M. Cardillo, Fatma Tat, Roberto Arrojo, Robert M. Sharkey, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 2526.
https://doi.org/10.1158/1538-7445.AM2012-2526
Published: 15 April 2012
View articletitled, Abstract 2526: Optimal cleavable linker for antibody-SN-38 conjugates for cancer therapy: Impact of linker's stability on efficacy
Journal Articles

Abstract 1798: Effective lymphoma and leukemia therapy with epratuzumab (anti-CD22 IgG) conjugated to SN-38 (Emab-SN-38), with enhanced activity in combination with veltuzumab (anti-CD20 IgG)

Robert M. Sharkey, Thomas M. Cardillo, Serengulam V. Govindan, David M. Goldenberg
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1798.
https://doi.org/10.1158/1538-7445.AM2011-1798
Published: 15 April 2011
View articletitled, Abstract 1798: Effective lymphoma and leukemia therapy with epratuzumab (anti-CD22 IgG) conjugated to SN-38 (Emab-SN-38), with enhanced activity in combination with veltuzumab (anti-CD20 IgG)